Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
K+ Channel Antagonist Market: Competitive Landscape, Pipeline, and Market Analysis 2023
K+ Channel Antagonist Market: Competitive Landscape, Pipeline, and Market Analysis 2023
A K+ channel antagonist is a type of drug that blocks or inhibits the activity of potassium (K+) channels in the body. By antagonizing these channels, the drug disrupts the normal function of potassium channels, leading to various physiological effects. The mechanism of action of K+ channel antagonists involves binding to specific sites on the potassium channels, thereby preventing potassium ions from passing through the channel pore. This blockade can result in membrane depolarization, alteration of action potentials, and modulation of cellular excitability K+ channel antagonists are used in the treatment of several medical conditions, including cardiac arrhythmias, hypertension (high blood pressure), epilepsy, and neuropathic pain. By modulating potassium channel activity, these drugs can help regulate electrical signaling in the heart, control blood pressure, reduce neuronal hyperexcitability, and alleviate pain associated with nerve damage. According to WHO, 1.28 billion adults aged 30–79 years worldwide have hypertension, most (two-thirds) living in low- and middle-income countries, and moreover, 46% of adults with hypertension are unaware that they have the condition.
The growth drivers of the K+ channel antagonist market include the increasing prevalence of cardiovascular diseases and neurological disorders that require the modulation of potassium channel activity for effective treatment, as well as advancements in drug discovery and development technologies leading to the introduction of new and more potent K+ channel antagonist drugs. Companies such as AstraZeneca, AbbVie, Pain Reform, Abbott, Astellas, Bayer, Blue Ash Therapy, and Circassia cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, Sequel is one such company that is currently conducting a clinical trial of the drug K201 for the treatment of arrhythmia.
Key Developments
In August 2019, Kissei Pharmaceutical launched Mitiglinide for type 2 diabetes mellitus in Taiwan
In December 2020, Wanbang Pharmaceutical received approval for the drug Lidocaine/ Prilocaine from the National Medical Products Administration (NMPA) to submit the investigational new drug (IND) for Clinical Trial Approval (CTA) for Premature ejaculation in China.
Approved K+ Channel Antagonists molecules:
K+ Channel Antagonist Pipeline Molecules
Clinical Activity and Development of K+ Channel Antagonists
In the K+ Channel Antagonist space, more than 25 companies are conducting more than 35 clinical trials in this category of drugs. For instance,
In January 2023, Soleno therapeutics presented results assessing the effect of Diazoxide Choline Extended-Release Tablet in People with Prader-Willi Syndrome published in the Journal of Clinical Endocrinology and Metabolism
In December 2021, Plethora Solutions completed a phase II trial for Premature ejaculation in the USA.
|
Product Name |
Total Studies |
|
AZD1305 |
13 |
|
K201 |
4 |
|
NTC-801 |
3 |
|
Budiodarone (ATI-2042) |
2 |
|
AZD7009 |
1 |
|
BAY2253651 |
1 |
|
SPS4251 |
1 |
|
ropivacaine depot (F-93) |
1 |
A K+ channel antagonist is a type of drug that specifically targets and inhibits potassium (K+) channels in the body. These channels play a crucial role in regulating electrical signals and maintaining proper cell function. By antagonizing these channels, the drug effectively blocks or reduces the flow of potassium ions, altering the electrical activity of cells. This can have various therapeutic effects depending on the specific target tissue or organ. K+ channel antagonists are widely used in cardiovascular medicine to treat conditions such as arrhythmias by stabilizing the heart's electrical activity. Additionally, they may have applications in neurology, immunology, and other fields where modulating potassium channel function is beneficial.
The global K+ Channel antagonist market is segmented into the United States, United Kingdom, Germany, Spain, France, Italy, and Japan. The overall US regional market analysis of K+ channel antagonists indicates a steady growth in demand and usage. These drugs are primarily used in cardiovascular medicine for treating arrhythmias. The market is driven by factors such as an increasing prevalence of cardiovascular diseases, advancements in drug development, and a growing aging population. However, regional variations in market size and competition exist, influenced by factors like healthcare infrastructure and regional disease patterns. The United States, being a frontrunner in the healthcare industry, holds a significant share of the market. The global sales of Multaq of Sanofi in the year 2021 were $329 million and out of which the USA sales were 292 million. Canada, on the other hand, is known for its well-established healthcare system and supportive regulatory framework, making it an attractive market for K+ Channel Antagonists. On the other hand, the K+ Channel Antagonist market in Europe has witnessed significant growth in recent years. Major countries driving this market include Germany, France, Italy, and Spain. These countries have a robust pharmaceutical industry, which is a key driver for the K+ Channel Antagonist market.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
The approved molecule of K+ Channel Antagonists is Gliclazide, Multaq (dronedarone), Brinavess (vernakalant), Pliaglis (lidocaine and tetracaine topical cream 7%), Dofetilide, and Glufast (mitiglinide).
The growth drivers of the K+ channel antagonist stimulator market include the increasing prevalence of cardiovascular diseases and neurological disorders that require the modulation of potassium channel activity for effective treatment, as well as advancements in drug discovery and development technologies leading to the introduction of new and more potent K+ channel antagonist drugs.
The major players in this space are BMS, Pfizer, Astellas, Roche, Sino Biopharm, Amgen, Ascentage Pharma, GSK, Novartis, and Takeda.
One of the main restraints of the K+ channel antagonist drug market is the presence of potential side effects and safety concerns associated with these medications. These can include cardiac arrhythmias, electrolyte imbalances, and other adverse reactions, which may limit their widespread use and adoption.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.